Method of Participation:
A statement of credit will be issued only upon receipt of completed evaluation forms, a completed post-test with a score of 70% or higher, and a completed attendance verification form. Your statement of credit will be e-mailed to you 6 to 8 weeks after receipt.
After reading "The Great Debate Part II: Should Managed Care Rely on Cost Sharing to Manage Big-ticket Biologics?" please complete the program evaluation and circle the 1 best answer to each of the following questions.
1. Any degree of copayment suppresses demand not only for inappropriate care, but also for necessary therapy.
2. There is a link between the degree of health literacy and activation a patient has and how healthy they are.
3. Some ways in which the value of a therapy can be shown to patients include:
4. Cost is usually one of the most cited reasons why patients discontinue needed therapy.
5. Remission in patients with Crohn's disease is associated with improvement in the following:
6. Increasing patient cost sharing is the most effective way to reduce healthcare costs while maintaining access to needed therapies.
7. The primary goal of patient cost sharing is:
8. Currently the fastest growing component of healthcare costs in the United States is:
9. Employers are concerned with ____ when evaluating healthcare coverage decisions for their employees.
10. The majority of healthcare cost increases in the United States are related to pharmaceutical products.
To enhance understanding of the challenges faced by managed care and employers when balancing access to expensive therapies with cost.
Managed care pharmacy directors, medical directors, and other managed care executives responsible for overseeing the use of biologics and managing them on behalf of health plans.
After completing this activity, participants should be able to:
Initial Live Release Date: October 7, 2005
Release Date: April 1, 2006
Expiration Date: March 31, 2007
If the participant has previously attended this program and requested or received credit, he/she may not request or receive credit for the home study version of the program.
There are no fees associated with this continuing education offering.
Genentech has provided the grant funds for this activity.
The University of Utah College of Pharmacy designates this continuing education activity for 1.5 credit hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Program Number: 068-999-05-042-H04.
The University of Utah College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The University of Utah School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Utah School of Medicine designates this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The University of Utah College of Pharmacy and the University of Utah School of Medicine do not recommend the use of any agent outside of the labeled indications.
Journal article learning activity.